Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 5249 (107th)

Safe Overseas Human Testing Act

referredUnited States· United States Congress· EN

Introduced

26 July 2002

Last action

26 July 2002 · Introduced

Status

Referred to the House Committee on International Relations.

Sponsors

Rep. Lantos, Tom [D-CA-12], Sen. Brown, Sherrod [D-OH], Rep. Smith, Christopher H. [R-NJ-4], Rep. Hilliard, Earl F. [D-AL-7], Rep. Watson, Diane E. [D-CA-33], Rep. Lee, Barbara [D-CA-12], Rep. Pallone, Frank [D-NJ-6], Rep. Stupak, Bart [D-MI-1], Rep. Napolitano, Grace F. [D-CA-32], Rep. Berman, Howard L. [D-CA-28], Rep. Ackerman, Gary L. [D-NY-5], Rep. Payne, Donald M. [D-NJ-10], Rep. Meeks, Gregory W. [D-NY-5], Rep. Hoeffel, Joseph M. [D-PA-13], Rep. Sherman, Brad [D-CA-32], Rep. Woolsey, Lynn C. [D-CA-6], Rep. Berkley, Shelley [D-NV-1], Rep. McKinney, Cynthia A. [D-GA-4], Rep. Ros-Lehtinen, Ileana [R-FL-27], Sen. Sanders, Bernard [I-VT], Rep. Allen, Thomas H. [D-ME-1], Rep. Doyle, Michael F. [D-PA-14]

Subjects

Healthcare

Source updated

19 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Safe Overseas Human Testing Act - Declares it is the policy of Congress to control the export of drugs and other test articles intended for overseas clinical investigations involving human participants in order to foster public health and safety, prevent injury to U.S. foreign policy, and preserve the credibility of the United States as a responsible trading partner. Requires a license approved by the President for the export of such test articles. Sets forth certain export license requirements, including that the license applicant shall: (1) identify each clinical investigation for which the test article is intended; and (2) submit proof that each of the protocols for every clinical investigation has been reviewed by an institutional review board and has, at a minimum, met substantially the same standards for the protection of the rights and welfare of human subjects as that required for Institutional Review Boards approval of protocols for clinical investigations (in the United States) of test articles pursuant to the Federal Food, Drug, and Cosmetic Act.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 26 July 2002

    Introduced

    Referred to the House Committee on International Relations.

    Source: IntroReferral

  2. 26 July 2002

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 26 July 2002

    Introduced

    Introduced in House

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 26 July 2002

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 26 July 2002

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 26 July 2002

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

No cross-record relationships stored yet.

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.